Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue 1, 2002, Pages 72-85

  De Witte, Theo ^a   Oosterveld, Margriet ^a   Span, Bart ^a   Muus, Petra ^a   Schattenberg, Anton ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTILEUKEMIC AGENT; BENZENE; BLEOMYCIN; CHLORMETHINE; CYTOTOXIC AGENT; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; INTERFERON; PREDNISONE; PROCARBAZINE; RETINOIC ACID; VINBLASTINE; VINCRISTINE; VITAMIN;

CHROMOSOME 11Q; CHROMOSOME 21Q; CHROMOSOME 5; CHROMOSOME 7; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; HISTOCOMPATIBILITY; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL TIME; SYNDROME DELINEATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LEUKEMIA, RADIATION-INDUCED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 0036244528     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2002.00057.x     Document Type: Review

References (86)

1. Proposals for the classification of the myelodysplastic syndromes
2. Occupational history and involvement of chromosomes 5 and 7 in acute nonlymphocytic leukemia
3. Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents
4. Myeloid leukemias and myelodysplastic syndromes: Chemical exposure, histologic subtype and cytogenetics in a case-control study
5. A case-control study of myelodysplastic syndromes among Japanese men and women
6. Therapy-related myelodysplastic syndromes
7. Biology and pathogenesis of the myelodysplastic syndromes
8. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
9. Mutations of the AML-1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis
10. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies
11. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: A single institution study
12. Different genetic pathways in leukogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
13. Environment and cancer: Who are susceptible?
14. Microsatellite instability and P53 mutations in therapy-related leukemia suggest mutator phenotype
15. Evidence of a treatment dose-response in acute nonlymphocytic leukemias which occur after therapy of nonHodgkin's lymphoma
16. Second acute leukemia and other malignancies following treatment for Hodgkin's disease
17. Second cancer risk following Hodgkin's disease: A 20-year follow-up study
18. Risk of leukemia following treatment for nonHodgkin's lymphoma
19. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
20. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and nonHodgkin's lymphoma
21. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
22. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphoma is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
23. Detection of abnormal pretransplant clones in progenitor cells of patients who develop myelodysplasia after autologous stem cell transplantation
24. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acyte myelogenous leukemia after treatment for non-Hodgkin's lymphoma
25. Secondary Leukemia and myelydysplasia after autografting for lymphoma: Results from the EBMT
26. Therapy-related acute myeloid leukemia and myelodysplasia after high-does chemotherapy and autologous stem cell transplantation
27. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: Assessment of risk factors
28. Benzene and the dose-related incidence of hematologic neoplasms in China
29. Benzene hematotoxicity
30. Metabolic polymorphisms and cancer susceptibility
31. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect
32. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia
33. Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukemia
34. Glutathione S-transferase gene deletions in myelodysplasia
35. Ethnic differences in the prevalence of homozygous deleted genotype of glutathione S-transferase theta
36. Polymorphic expression of the gluthathione S-transferase P1 gene and its susceptibility to Barrett's oesophagus and oesophageal carcinoma
37. NAD(P)H. quinone reductase: Polymorphisms and allele frequencies in Caucasian, Chinese and Canadian native Indian Inuit populations
38. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C → T mutation and rapid fractional excretion of chlorzoxazone
39. Prevalence of the inactivating 609X→T polymorphism in the NAD(P)H. quinone oxidsoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
40. Therapy-related leukemias: Susceptibility, prevention and treatment
41. Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features
42. Refractory anemia with excess of blasts in transformation. Hematologic and clinical study of 52 patients
43. Effect of chemotherapy for the dysmyelopoietic syndrome
44. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia
45. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia
46. High-dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study
47. Treatment of therapy-related leukemia and myelodysplasti syndrome
48. Multidrug resistance in hematopoietic cell lines, myelodysplastic syndromes, and acute myeloblastic leukemia
49. High expression of the multidrug resistance P-glycoprotein in high risk myelodysplasia is associated with immature phenotype
50. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy
51. The role of aggressive chemotherapy in the treatment of myelodysplastic syndromes
52. Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy
53. Therapy-related myelodysplastic syndrome and leukemia with no unfavourable cytogenetic findings have a good response to intensive chemotherapy: A report on 15 cases
54. The importance of diagnostic cytogenetics on outcome in AML, analysis of 1612 patients entered into MRC AML10 trial
55. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution
56. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
57. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer. (EORTC-LCG)
58. Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis
59. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes
60. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes
61. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia
62. Autologous bone marrow transplantation with marrow purged by Mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): A pilot study
63. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission
64. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodys-plastic syndromes
65. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
66. Genotypically nonidentical related donors for transplantation of patients with myelodys-plastic syndromes: Comparison with unrelated donor transplantation and autologous stem cell transplantation
67. Allogeneic bone marrow transplantation in a patient with acute myeloid leukemia secondary to Hodgkin's disease
68. Allogeneic transplantation in the treatment of preleukemia
69. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: A survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
70. Hematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
71. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: Along-term study of 70 patients - Report of the French society of bone marrow transplantation
72. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
73. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia
74. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia
75. Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease
76. Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease
77. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
78. A fludarabine based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation fro related or unrelated donors in patients with myelodysplastic syndrome
79. Effect of diagnosis (refractory anemia, with excess of blasts, refractory anemia with excess of blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
80. Analysis of 462 transplantations from unrelated donors facilitated by the National marrow Donor Program
81. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey
82. Unrelated donor transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia
83. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia
84. Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia
85. Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies